Early second radiofrequency ablation treatment gave rise to significantly greater nodule shrinkage at 12 months than single-session treatment for large-volume benign thyroid nodules.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 39455384.
- Also identified by DOI 10.1016/j.surg.2024.06.078.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Radiofrequency ablation (RFA) is an effective nonsurgical treatment for symptomatic benign thyroid nodules. Large-volume nodules (≥20-mL) often require 2 or more radiofrequency ablation sessions to achieve desirable shrinkage but the optimal interval between sessions remains unknown. We hypothesized that early (within 6 months) retreatment could improve nodule shrinkage. This study compared the 12-month volume reduction rate (VRR) and complications between single-session radiofrequency ablation and 2-session radiofrequency ablation within 6 months for large benign thyroid nodules. Consecutive patients with cytologically proven benign thyroid nodules ≥20 mL undergoing radiofrequency ablation were prospectively assigned to undergo either single-session (group 1) or 2-session radiofrequency ablation within 6 months (group 2). All were followed up for at least 12 months after the initial radiofrequency ablation. Volume reduction rate was calculated as (baseline - current volume)/baseline volume × 100%. Complications were documented. Out of 67 nodules ≥20 mL that underwent radiofrequency ablation, 43 nodules (group 1: n = 23, group 2: n = 20) from 42 patients were analyzed. Both groups had comparable baseline nodule volumes (33.2 ± 14.9 mL vs 34.3 ± 12.5 mL) and clinical parameters (P > .05). The 6-month volume reduction rate was comparable (65.7 ± 13.2% vs 68.6 ± 13.3%, P = .264) but the 12-month volume reduction rate was significantly greater in group 2 (65.9 ± 17.1% vs 75.6 ± 11.5%, P = .019). Group 2 nodules continued to shrink from 6 to 12 months (P = .012), whereas group 1 nodules did not (P = .503). Two-session radiofrequency ablation within 6 months was the only significant factor associated with a 12-month volume reduction rate of ≥75% (odds ratio 4.375, 95% confidence interval 1.210-15.812, P = .024). No vocal cord paresis or hematoma requiring reoperation occurred. Early retreatment with 2-session radiofrequency ablation within 6 months was safe and led to significantly greater nodule shrinkage at 12 months than single-session radiofrequency ablation.
Medical subject headings
- Thyroid Nodule
- Radiofrequency Ablation